AbleDocs Inc. Announces the Acquisition of Diversa Docs ApS to Further the Reach of the Worldwide Leader in Document Accessibility Products and Services Throughout Scandinavia
6.4.2021 15:42:00 EEST | Business Wire | Press release
AbleDocs Inc. the leading PDF accessibility product and service provider, and Diversa Docs ApS, a recognized leader in PDF and Web Accessibility services announce their coming together to become the Scandinavian leader in PDF accessibility products and services.
With a long-standing record of collaboration, both companies’ founders and leadership teams couldn’t be more excited to leverage each other’s capabilities to offer their existing and new clients the best in PDF/UA products and services.
“Diversa Docs has consistently been recognized as a leader in excellence in delivering PDF/UA compliant and accessible PDFs, and this acquisition will allow our combined client base to benefit from the experience, and scale of our products and services throughout Scandinavia,” said AbleDocs’ President (GLOBAL), Adam Spencer. “With their amazing team and end user focused approach, they are the ideal partner for AbleDocs. With our combined effort, we can drive the creation of next-generation PDF accessibility services and solutions,” said Vice-President (SCANDINAVIA), Jens Bjerre Kirkegaard.
“Accessibility has always appealed to me because it combines a technical field with a humanistic one,” says CEO of Diversa Docs, Asbjørn Fangel-Hansen.
“Having worked for 12 years in the Danish public sector within accessibility and most recently as the owner of one of the leading companies in the field of accessibility in Denmark, I am very honored to be part of one of the absolute leading global players when it comes to accessible documents,” adds Fangel-Hansen.
The combination of AbleDocs and Diversa Docs will widen the global presence of AbleDocs for products, services, solution development, training, and localized document accessibility support across 49 languages to ensure clients receive the best offerings possible.
About Diversa Docs
Diversa Docs ApS was founded by Lars Holm-Sørensen and Asbjørn Fangel-Hansen in 2019 as a sister company to Diversa ApS. Since then, the company has developed into one of the leaders in Denmark in terms of document accessibility and the area in general.
About AbleDocs Inc.
AbleDocs was founded in 2019 as a conglomerate of PDF accessibility remediation service providers and has grown to have operations in Canada, Denmark, Germany, Switzerland, and the United States. Its founders have been making documents accessible for over 150 years combined experience and has since expanded its offerings to include a completely new approach to document accessibility strategies to include products for high volume document accessibility, document accessibility testing.
AbleDocs is the only company in the world to guarantee the compliance of every file they produce and back it with a $10,000,000 liability guarantee. Current offerings include ADService, ADGateway, ADScan, ADStream, ADLegacy, ADForms, axesWord and axesPDF.
For more information, visit https://www.abledocs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005229/en/
Contact information
For media inquiries:
Gary MacKay, mediainquiries@abledocs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom